Wegovy Tablets Results: What the OASIS Trials Show

Wegovy Tablets Results: What the OASIS Trials Show

The conversation around weight management is evolving, with new treatments offering more options than ever before. For years, Wegovy has been known as a once-weekly injectable medication. Since December 22, 2025, the U.S. FDA has also approved a daily oral tablet containing the same active ingredient, semaglutide, at a maintenance dose of 25 mg.

This shift from an injection to a pill has generated a lot of questions, especially about results. How effective is the tablet? How quickly does it work? To answer these, we can look directly at the data from the major clinical trial program, known as OASIS. This article provides a clear, realistic look at the weight loss timeline shown in these studies. Consult your healthcare provider before starting any medication.

What Were the OASIS Trials?

Before diving into the results, it’s helpful to understand where the information comes from. The OASIS (Oral Semaglutide Treatment Effect in People with Obesity) program is a series of clinical trials of daily oral semaglutide for chronic weight management, testing doses including 25 mg and 50 mg.

Two studies matter most:

• OASIS 4 tested the 25 mg tablet that was approved as Wegovy tablets. It enrolled 307 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes, and ran for 64 weeks.
• OASIS 1 tested a higher 50 mg dose (not the approved product) in 667 adults with obesity, or overweight with at least one weight-related health condition, without type 2 diabetes. The trial ran for 68 weeks (about 15 and a half months).

Most of the timeline below draws on OASIS 1, which reported results over time in detail.

It's crucial to note that this wasn't just about taking a pill. Every participant in these trials, including those who received a placebo, also received counseling on lifestyle changes. This included guidance on a reduced-calorie diet and increased physical activity. The results reflect the combination of the medication and these important lifestyle efforts.

A Realistic Timeline for Wegovy Tablet Results

The OASIS 1 trial provides a detailed map of what to expect over time. Weight loss is a gradual process, and the study shows a clear pattern of steady progress rather than an overnight transformation.

Early Weeks: The Titration Period

Treatment with medications like semaglutide typically begins with a process called titration. This means you start on a low dose, which is gradually increased over the first few months. For the approved Wegovy tablets, the dose steps up every 30 days (1.5 mg, 4 mg, 9 mg) to reach 25 mg at about day 91; your prescriber may delay a step if side effects are hard to tolerate. The primary goal of this period is to help your body adjust to the medication and minimize potential side effects, such as nausea or other gastrointestinal discomfort.

During these initial weeks, many people begin to notice the first effects of the medication, primarily a reduction in appetite and an increased feeling of fullness after meals. While some weight loss may occur during this phase, the most significant changes are usually yet to come. The focus is on consistency and establishing a routine.

The First Three Months (to Week 20)

As the dose is gradually optimized, weight loss tends to become more consistent. By the 20-week mark of the OASIS 1 trial, participants taking oral semaglutide had achieved a meaningful reduction in their body weight.

This phase is often highly motivating as the combined effects of the medication and lifestyle adjustments start to produce visible results. The early changes in appetite and fullness translate into consistent, measurable progress on the scale. It's a period where new, healthier habits begin to feel more established.

Reaching the Mid-Point (to Week 40)

By the middle of the trial, participants continued to see steady weight loss. The journey of chronic weight management is a marathon, not a sprint, and the data reflects this. The progress seen in the first few months builds, leading to more substantial health and wellness improvements.

At this stage, many participants in the trial would have experienced significant reductions not just in weight, but also in related health markers like waist circumference. This sustained progress underscores the importance of sticking with the treatment plan long-term.

The Full Study Duration (68 Weeks)

The headline result from the OASIS 1 trial came at its conclusion after 68 weeks. Participants who took the 50 mg oral semaglutide tablet, in combination with lifestyle intervention, achieved an average weight loss of 15.1% of their initial body weight.

To put that in perspective, a person weighing 230 pounds at the start of the study would have lost, on average, about 35 pounds.

Just as importantly, the group receiving a placebo (a pill with no active ingredient) alongside the same lifestyle counseling lost an average of 2.4% of their body weight. The significant difference between the two groups demonstrates the powerful effect of the medication when added to diet and exercise. Furthermore, about 85% of those taking the 50 mg tablet lost 5% or more of their body weight (versus 26% on placebo), a level considered clinically significant for improving health.

For the approved 25 mg tablet, the OASIS 4 trial found average weight loss at 64 weeks of 13.6% versus 2.4% with placebo when everyone was counted, and about 16.6% for people who stayed on treatment. About 76% of people on the 25 mg tablet lost at least 5% of their body weight, versus 31% on placebo.

Beyond the Pill: What Affects Your Progress?

The OASIS trial results are averages, and individual experiences will always vary. Several factors play a critical role in how successful treatment can be.

The Role of Lifestyle Changes

It cannot be overstated: the medication is a tool, not a replacement for healthy habits. The success seen in the OASIS trials was achieved by people who were also working to improve their diet and increase their physical activity. The tablet helps make these changes more manageable by regulating appetite and promoting satiety, but the commitment to a healthier lifestyle remains fundamental.

Consistency is Key

Oral semaglutide is designed to be taken once a day. The label instructions are to take it in the morning on an empty stomach with no more than 120 ml (4 ounces) of plain water, swallow it whole, and then wait at least 30 minutes before eating, drinking, or taking other oral medications. If a dose is missed, the US label says to skip it and take the next dose the following day; never take two tablets in one day. Adhering to this routine consistently is essential for ensuring the medication is properly absorbed and can work effectively.

Your Individual Health Profile

Everyone’s body is different. Factors like your starting weight, your unique metabolism, and the presence of other health conditions can influence your weight loss journey. Progress may be faster for some and slower for others, and that’s perfectly normal. The key is to focus on your personal trend of progress in consultation with your healthcare team.

Putting It All Together: A Long-Term Perspective

The OASIS trials show that oral semaglutide can lead to significant, clinically meaningful weight loss over the long term. The results unfold gradually, with progress building steadily over more than a year.

The journey begins with an adjustment period, followed by consistent weight loss that, for the average participant, reached 15.1% at 68 weeks with the 50 mg dose in OASIS 1 and 13.6% at 64 weeks with the approved 25 mg dose in OASIS 4. This success was achieved through a powerful partnership: the medication supporting the body, and the individual committing to durable lifestyle changes.

Side effects are mostly gastrointestinal (nausea, vomiting, diarrhoea, constipation). Seek urgent medical help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or if you cannot keep fluids down, and tell your prescriber about mood changes, vision changes if you have diabetic eye disease, or plans for surgery or pregnancy.

Ultimately, this treatment represents another valuable option in the toolkit for chronic weight management, helping individuals achieve their health goals as part of a comprehensive plan. Consult your healthcare provider before starting any medication.

Sources

1. ACC.org trial summary, Oral Semaglutide Treatment Effect in People With Obesity (OASIS 1): https://www.acc.org/latest-in-cardiology/clinical-trials/2023/07/17/14/19/oasis-1
2. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg for the treatment of adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext
3. MedlinePlus — semaglutide tablets: https://medlineplus.gov/druginfo/meds/a619057.html
4. U.S. National Library of Medicine. Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05035095
5. Wharton, S., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med, 393(11), 1077–1087. doi:10.1056/NEJMoa2500969
6. Wegovy (semaglutide) injection and tablets prescribing information, U.S. FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf